Patent · US Active

Materials and methods for engineering cells and uses thereof in immuno-oncology

US11166985B2 · kind B2 · utility

7Cited by

44References

14Claims

0Family size

Assignee

CRISPR THERAPEUTICS AG · CH

Inventors

Jonathan Alexander Terrett · Slough, GB
Demetrios Kalaitzidis · Cambridge, US
Lawrence Klein · Cambridge, US

Key dates

Filing date	Jul 29, 2020
Grant date	Nov 9, 2021
Priority date	—
Expiry date	Jul 29, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2750/14143
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.